Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
23.43
+1.32 (5.97%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 222 | 150 | 127 | 206 | 148 | Upgrade
|
| Short-Term Investments | 759 | 828 | 632 | 803 | 351 | Upgrade
|
| Cash & Short-Term Investments | 981 | 978 | 759 | 1,009 | 499 | Upgrade
|
| Cash Growth | 0.31% | 28.85% | -24.78% | 102.20% | -31.52% | Upgrade
|
| Accounts Receivable | 11 | 20 | 38 | 39 | 745 | Upgrade
|
| Other Receivables | 5 | 5 | 4 | 4 | 2 | Upgrade
|
| Receivables | 16 | 25 | 42 | 43 | 747 | Upgrade
|
| Prepaid Expenses | 10 | 13 | 30 | 15 | 16 | Upgrade
|
| Total Current Assets | 1,007 | 1,016 | 831 | 1,067 | 1,262 | Upgrade
|
| Property, Plant & Equipment | 98 | 112 | 143 | 135 | 137 | Upgrade
|
| Long-Term Investments | 29 | 14 | 107 | 129 | 182 | Upgrade
|
| Other Long-Term Assets | 5 | 8 | 14 | 14 | 11 | Upgrade
|
| Total Assets | 1,139 | 1,150 | 1,095 | 1,345 | 1,592 | Upgrade
|
| Accounts Payable | 42 | 18 | 17 | 20 | 10 | Upgrade
|
| Accrued Expenses | 122 | 96 | 62 | 70 | 47 | Upgrade
|
| Current Portion of Leases | 13 | 12 | 11 | 3 | - | Upgrade
|
| Current Income Taxes Payable | 1 | 1 | - | - | 2 | Upgrade
|
| Current Unearned Revenue | 35 | 85 | 91 | 97 | 102 | Upgrade
|
| Other Current Liabilities | 18 | 14 | 3 | 3 | 5 | Upgrade
|
| Total Current Liabilities | 231 | 226 | 184 | 193 | 166 | Upgrade
|
| Long-Term Debt | 120 | 69 | 19 | - | - | Upgrade
|
| Long-Term Leases | 86 | 99 | 110 | 117 | 117 | Upgrade
|
| Long-Term Unearned Revenue | 43 | 234 | 307 | 355 | 462 | Upgrade
|
| Other Long-Term Liabilities | 28 | 37 | 13 | 23 | 5 | Upgrade
|
| Total Liabilities | 508 | 665 | 633 | 688 | 750 | Upgrade
|
| Common Stock | 2,116 | 1,617 | 1,311 | 1,206 | 1,118 | Upgrade
|
| Retained Earnings | -1,485 | -1,132 | -849 | -542 | -275 | Upgrade
|
| Comprehensive Income & Other | - | - | - | -7 | -1 | Upgrade
|
| Total Common Equity | 631 | 485 | 462 | 657 | 842 | Upgrade
|
| Shareholders' Equity | 631 | 485 | 462 | 657 | 842 | Upgrade
|
| Total Liabilities & Equity | 1,139 | 1,150 | 1,095 | 1,345 | 1,592 | Upgrade
|
| Total Debt | 219 | 180 | 140 | 120 | 117 | Upgrade
|
| Net Cash (Debt) | 791 | 812 | 726 | 1,018 | 564 | Upgrade
|
| Net Cash Growth | -2.59% | 11.85% | -28.68% | 80.50% | -20.94% | Upgrade
|
| Net Cash Per Share | 7.36 | 9.01 | 9.81 | 14.14 | 7.62 | Upgrade
|
| Filing Date Shares Outstanding | 125.35 | 105.84 | 90.86 | 73.01 | 71.06 | Upgrade
|
| Total Common Shares Outstanding | 125.3 | 92.2 | 75.5 | 72.9 | 70.78 | Upgrade
|
| Working Capital | 776 | 790 | 647 | 874 | 1,096 | Upgrade
|
| Book Value Per Share | 5.04 | 5.26 | 6.12 | 9.01 | 11.90 | Upgrade
|
| Tangible Book Value | 631 | 485 | 462 | 657 | 842 | Upgrade
|
| Tangible Book Value Per Share | 5.04 | 5.26 | 6.12 | 9.01 | 11.90 | Upgrade
|
| Machinery | 32 | 31 | 27 | 20 | 16 | Upgrade
|
| Construction In Progress | 1 | 1 | 1 | 4 | 2 | Upgrade
|
| Leasehold Improvements | 57 | 56 | 54 | 34 | 32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.